REG - Citigroup Global Mkt Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI)

Takeda Pharmaceutical CoAnnouncement

07/01/2019 10:15

RNS Number : 3682M
Citigroup Global Markets Limited
07 January 2019
 


 
 
 
 
FORM 8.5 (EPT/RI)
 
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
 
1. KEY INFORMATION
 




(a) Name of exempt principal trader:


Citigroup Global Markets Limited




(b) Name of offeror/offeree in relation to whose

relevant securities this form relates:

Use a separate form for each offeror/offeree


Takeda Pharmaceutical Company Limited




(c) Name of the party to the offer with which exempt

principal trader is connected:


Shire plc




(d) Date dealing undertaken:


4 January 2019




(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"


YES

Shire plc




 
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a) Purchases and sales
 




Class of relevant security


Purchases/ sales


Total number of securities


Highest price per unit paid/received


Lowest price per unit paid/received




Ordinary


Purchase


595,690


USD 34.5622


USD 34.4442




Ordinary


Purchase


990,190


JPY 3753.0000


JPY 3604.7143




Ordinary


Sale


595,690


USD 34.5622


USD 34.4442




Ordinary


Sale


1,590,590


JPY 3753.0000


JPY 3620.0000




ADS


Purchase


100,000


USD 17.5559


USD 17.4292




ADS


Sale


100,000


USD 17.5559


USD 17.4292




 
(b) Cash-settled derivative transactions
 
 




Class of relevant security


Product description  

e.g. CFD


Nature of dealing

e.g. opening/closing a

long/short position,

increasing/reducing a

long/short position


Number of reference securities


Price per unit




  


  


  


  


  




 
(c) Stock-settled derivative transactions (including options)
 
(i) Writing, selling, purchasing or varying
 




Class of relevant security


Product description  

e.g. call option


Writing, purchasing,

selling,

varying etc.


Number of securities to

which option relates


Exercise price per unit


Type

e.g. American,

European etc.


Expiry date


Option money paid/ received per unit




  


  


  


  


  


  


  


  




 
 
(ii) Exercise
 
 




Class of relevant security


Product description  

e.g. call option


Exercising/ exercised against


Number of

securities


Exercise price per unit




  


  


  


  


  




 
(d) Other dealings (including subscribing for new securities)
 
 




Class of relevant security


Nature of dealing

e.g. subscription, conversion


Details


Price per unit

(if applicable)




  


  


  


  




 
3. OTHER INFORMATION
 
(a) Indemnity and other dealing arrangements
 




Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with

a party to the offer:
 
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"




None




 
(b) Agreements, arrangements or understandings relating to options or derivatives
 




Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
 
If there are no such agreements, arrangements or understandings, state "none"




None




 




Date of disclosure:


7 January 2019




Contact name:


Connor McLaughlin




Telephone number:


02895 955 328




 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information

Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERMMGGMGNGGLZM